Inversago Pharma Initiates Clinical Trials, with a Phase 1 study of INV-101, the Company’s Lead Peripheral CB1 Blocker
MONTREAL–(BUSINESS WIRE)–#CB1blocker–Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has initiated a Phase…